Floatz logo

cd19/bcma-targeted car-t cells

Non-Hodgkin's Lymphoma Refractory

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Non-Hodgkin's Lymphoma Refractory cohort.

Asset / SponsorPhaseRating
Autologous Car19 T Lymphocytes
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 1CC
Rpm Cd19-Mbil15-Car-T Cells
Eden BioCell Ltd.
Phase 1CC

Same molecule, other indications

cd19/bcma-targeted car-t cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →
B Cell LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →